Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib added to escitalopram for major depressive disorder
IRCT20210109049979N1Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Apr 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Escitalopram + celecoxib with Escitalopram + placebo (2 arms). Primary endpoint: Improvement in symptoms of major depressive disorder. Started Apr 2021; status: completed.
02
Drugs
celecoxibescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20210109049979N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210109049979N1.